FENTANYL SYSTEM- fentanyl patch

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Buy It Now

Active ingredient:

Fentanyl (UNII: UF599785JZ) (Fentanyl - UNII:UF599785JZ)

Available from:

Lake Erie Medical DBA Quality Care Products LLC

INN (International Name):

Fentanyl

Composition:

Fentanyl 25 ug

Administration route:

TRANSDERMAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Fentanyl transdermal system is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Limitations of Use - Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ], reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be o

Product summary:

Fentanyl transdermal system is supplied in cartons containing 5 individually packaged systems. See chart for information regarding individual systems. * This lowest dosage is designated as 12 mcg/h (however, the actual dosage is 12.5 mcg/h) to distinguish it from a 125 mcg/h dosage that could be prescribed by using multiple patches. Store in original unopened pouch. Store up to 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Authorization status:

Abbreviated New Drug Application

Patient Information leaflet

                                FENTANYL SYSTEM- FENTANYL PATCH
Lake Erie Medical DBA Quality Care Products LLC
----------
Medication Guide
Fentanyl (fen' ta nil) transdermal system, CII
Fentanyl Transdermal System is:
•
A strong prescription pain medicine that contains an opioid (narcotic)
that is used to manage pain
severe enough to require daily around-the-clock, long-term treatment
with an opioid, in people who
are already regularly using opioid pain medicine, when other pain
treatments such as non-opioid pain
medicines or immediate-release opioid medicines do not treat your pain
well enough or you cannot
tolerate them.
•
A long-acting (extended-release) opioid pain medicine that can put you
at risk for overdose and
death. Even if you take your dose correctly as prescribed you are at
risk for opioid addiction, abuse,
and misuse that can lead to death.
•
Not for use to treat pain that is not around-the-clock.
Important information about Fentanyl Transdermal System:
•
Get emergency help right away if you use too much fentanyl transdermal
system (overdose). When
you first start taking fentanyl transdermal system, when your dose is
changed, or if you take too
much (overdose), serious or life threatening breathing problems that
can lead to death may occur.
•
Taking fentanyl transdermal system with other opioid medicines,
benzodiazepines, alcohol, or other
central nervous system depressants (including street drugs) may cause
sever drowsiness, decreased
awareness, breathing difficulties, with slow or shallow breathing,
coma, and death.
•
Never give anyone else your fentanyl transdermal system. They could
die from using it. Store
fentanyl transdermal system away from children and in a safe place to
prevent stealing or abuse.
Selling or giving away fentanyl transdermal system is against the law.
•
If the patch accidentally sticks to a family member while in close
contact, take the patch off, wash the
area with water, and get emergency help right away because an
accidental exposure to fentanyl
transdermal system can lead to death or oth
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                FENTANYL SYSTEM- FENTANYL PATCH
LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
FENTANYL TRANSDERMAL
SYSTEM SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
FENTANYL TRANSDERMAL
SYSTEM.
FENTANYL TRANSDERMAL SYSTEM FOR TRANSDERMAL ADMINISTRATION, CII
INITIAL U.S. APPROVAL: 1968
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY
DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME;
CYTOCHROME P450 3A4 INTERACTION, RISK OF INCREASED FENTANYL ABSORPTION
WITH APPLICATION OF EXTERNAL HEAT; AND RISKS FROM CONCOMITANT USE OF
BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
FENTANYL TRANSDERMAL SYSTEM EXPOSES USERS TO RISKS OF ADDICTION,
ABUSE, AND
MISUSE, WHICH CAN LEAD TO OVERDOSE AND DEATH. ASSESS PATIENT'S RISK
BEFORE
PRESCRIBING, AND MONITOR REGULARLY FOR THESE BEHAVIORS OR CONDITIONS.
(5.1)
SERIOUS, LIFE-THREATENING, OR FATAL RESPIRATORY DEPRESSION MAY OCCUR.
MONITOR CLOSELY,
ESPECIALLY UPON INITIATION OR FOLLOWING A DOSE INCREASE. (5.2)
ACCIDENTAL EXPOSURE TO FENTANYL TRANSDERMAL SYSTEM, ESPECIALLY IN
CHILDREN, CAN
RESULT IN FATAL OVERDOSE OF FENTANYL. (5.3)
PROLONGED USE OF FENTANYL TRANSDERMAL SYSTEM DURING PREGNANCY CAN
RESULT IN
NEONATAL OPIOID WITHDRAWAL SYNDROME, WHICH MAY BE LIFE-THREATENING IF
NOT
RECOGNIZED AND TREATED. IF OPIOID USE IS REQUIRED FOR A PROLONGED
PERIOD IN A
PREGNANT WOMAN, ADVISE THE PATIENT OF THE RISK OF NEONATAL OPIOID
WITHDRAWAL
SYNDROME AND ENSURE THAT APPROPRIATE TREATMENT WILL BE AVAILABLE.
(5.4)
CONCOMITANT USE WITH CYP 3A4 INHIBITORS (OR DISCONTINUATION OF CYP 3A4
INDUCERS)
CAN RESULT IN A FATAL OVERDOSE OF FENTANYL. (5.5)
EXPOSURE OF THE FENTANYL TRANSDERMAL SYSTEM APPLICATION SITE AND
SURROUNDING AREA
TO DIRECT EXTERNAL HEAT SOURCES HAS RESULTED IN FATAL OVERDOSE OF
FENTANYL. WARN
PATIENTS TO AVOID EXPOSING THE FENTANYL TRANSDERMAL SYSTEM APPLICATION
SITE AND
SURROUNDI
                                
                                Read the complete document
                                
                            

Search alerts related to this product